Navigation Links
Trial suggests statin may affect markers associated with progression of HIV
Date:2/16/2011

A recent multicenter clinical trial of atorvastatin, a type of cholesterol-lowering drug, found that although the drug did not inhibit plasma HIV RNA levels, it did inhibit expression of cellular markers of immune activation and inflammation in patients with HIV infection. Since immune activation and inflammation are associated with progression of HIV infection, the implication is that the statin may inhibit disease progression and help in the infection's management. The findings are in a study, available online, published in The Journal of Infectious Diseases.

The investigators, led by Anuradha Ganesan, MD, of the National Naval Medical Center and the Infectious Disease Clinical Research Program in the Department of Preventive Medicine and Biometrics at the Uniformed Services University of the Health Sciences in Bethesda, Md., randomized 22 HIV-1-infected patients not on antiretroviral therapy and with cholesterol levels lower than those requiring statin therapy in a double-blind protocol of high-dose drug or placebo for eight weeks. After a four-to-six-week washout phase, each group was switched to the other treatment for another eight weeks.

The primary objective was to study the effect of atorvastatin on plasma HIV-1 RNA levels, as previous studies had shown conflicting results. The effect on cellular markers of immune activation was a secondary objective. HIV-1 RNA levels were not significantly affected by the drug, but levels of such immune activation markers as CD38 and HLA-DR on CD4 and CD8 T cells were reduced.

The researchers noted that their findings with atorvastatin suggest that understanding the mechanism by which statins affect immune markers may identify new approaches for the management of HIV infection. They point out, however, that their trial was not designed to demonstrate clinical benefits, for which larger studies of longer duration are needed.

In an accompanying editorial, Andrew Carr, MD, of St. Vincent's Hospital in Sydney, Australia, agreed, noting that "a very large study would probably be required to determine whether potentially positive effects of statin therapy on inflammatory biomarkers will translate into less HIV disease progression."


'/>"/>

Contact: John Heys
jheys@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. Women More Likely to Fail Treatment for Atrial Fibrillation
2. Single gene mutation induces endometrial cancer
3. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
4. MCG to conduct first FDA-approved stem cell trial in pediatric cerebral palsy
5. In Tests, Implanted Monitor Detects Atrial Fibrillation
6. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
7. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday
10. WellPoint/Blue Cross Liver Transplant Denial Trial Begins Today, Illustrates Need for Toughening of White House Reform Plan
11. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 21, 2017 , ... Caronlab Australia, an ... the January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding ... the quality of its beauty and wellness products. At this trade show, the company ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats ... of its owner and founder. As Oat is recognized globally as one of the ... personally as he believes it is a move to sow the seed of good ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern ... has recently joined their multi-specialty medical group. The dermatology practice provides general ... , “We’re excited to add this excellent dermatology practice to our group’s medical ...
(Date:1/21/2017)... Austin, Texas (PRWEB) , ... January 21, 2017 ... ... surgeries performed by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its ... features two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ ...
(Date:1/20/2017)... ... ... Overseer at The House of Yahweh has posted a new publication this week pleading to ... time like no other and society needs to understand the only way to help make ... to sound like an old bible beater because religion has a bad rap these days ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 ... "US Clinical Laboratory Testing Market By Type of Test (Tumor, ... Independent), & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS ... ... an attractive destination for healthcare services, market segments, especially clinical ...
(Date:1/21/2017)... Calif. , Jan. 20, 2017 ARMO ... 1b clinical data on the Company,s lead investigational immuno-oncology ... Symposium, co-sponsored by the American Society of Clinical Oncology ... San Francisco, CA. "AM0010 ... activated CD8 + T cells in the blood ...
(Date:1/21/2017)... NEW YORK , Jan. 20, 2017  Faruqi & ... in KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: ... against the Company and certain officers and directors and underwriters ... "IPO") to seek the role of lead plaintiff. ... District Court for Johnson County ...
Breaking Medicine Technology: